Pfizer Inc. $PFE Position Increased by Westpac Banking Corp

Westpac Banking Corp grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 16.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 262,876 shares of the biopharmaceutical company’s stock after purchasing an additional 36,846 shares during the period. Westpac Banking Corp’s holdings in Pfizer were worth $6,698,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Grey Fox Wealth Advisors LLC acquired a new stake in Pfizer during the third quarter worth about $29,000. Howard Hughes Medical Institute acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $30,000. True Wealth Design LLC lifted its holdings in shares of Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 974 shares during the last quarter. Darwin Wealth Management LLC acquired a new position in Pfizer during the 2nd quarter valued at approximately $32,000. Finally, Evelyn Partners Asset Management Ltd bought a new position in Pfizer during the 2nd quarter worth $33,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of Pfizer stock opened at $27.11 on Thursday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The stock has a market cap of $154.11 billion, a PE ratio of 19.93 and a beta of 0.47. The company’s 50-day moving average price is $26.04 and its two-hundred day moving average price is $25.37.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The business had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the previous year, the firm earned $0.63 EPS. The business’s revenue for the quarter was down 1.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.3%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is 126.47%.

Analysts Set New Price Targets

PFE has been the subject of several analyst reports. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, February 4th. TD Cowen restated a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Citigroup started coverage on Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective for the company. Finally, UBS Group started coverage on Pfizer in a research report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $27.70.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA gives full approval to Pfizer’s BRAFTOVI combination for first‑line metastatic colorectal cancer — a clear commercial positive for oncology revenue and uptake. Read More.
• Positive Sentiment: Pfizer secures China commercialization partner (Sciwind) for a next‑generation weight‑loss GLP‑1 candidate, expanding market access in a high‑growth obesity/diabetes segment and unlocking up to ~$495M in deal value. Read More.
• Positive Sentiment: Dividend narratives strengthen investor interest — coverage pieces highlight Pfizer’s high yield and management’s commitment to the payout, supporting income‑oriented demand. Read More.
• Neutral Sentiment: Pfizer updated clinical activity in China (pneumococcal vaccine Phase 1) — constructive for long‑term vaccine opportunity but near‑term commercial impact is unclear. Read More.
• Neutral Sentiment: Industry pieces and comparisons (Novo Nordisk, J&J, large‑cap pharma commentary) are placing Pfizer within a broader sector narrative about defensiveness and AI‑driven R&D — useful context but not company‑specific catalysts. Read More.
• Negative Sentiment: RBC Capital initiated coverage with an Underperform/“$25” target and warned of an expected $15B–$20B structural revenue decline through 2030 — a significant bearish forecast that pressures valuation expectations. Read More.
• Negative Sentiment: Zacks moved Pfizer from “strong sell” to “hold,” improving its tone but reflecting continued analyst caution; RBC/other outlets are still negative which keeps analyst sentiment mixed. Read More.
• Negative Sentiment: Pfizer terminated an early‑stage ulcerative colitis study (Phase 1b), representing a pipeline setback and incremental downside risk to future growth prospects. Read More.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.